stockrow
Friday 6 November 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
154.46
11.27
+7.87%
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Net income
Belite Bio, Inc. Sponsored ADR's net income for fiscal 2025 was −$77.6M, compared with −$36.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$77.6M. Over the past ten years it has ranged from −$77.6M (fiscal 2025) to −$5.8M (fiscal 2020) — the current reading is the lowest in ten years. Net income has fallen for 5 consecutive fiscal years. Belite Bio, Inc. Sponsored ADR ranks 388th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$77.6M | — |
| FY2024 | −$36.1M | — |
| FY2023 | −$31.6M | — |
| FY2022 | −$12.6M | — |
| FY2021 | −$9.7M | — |
| FY2020 | −$5.8M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Dec 2025 | −$25.3M | — |
| Sep 2025 | −$52.3M | — |
| Dec 2024 | −$10.1M | — |
| Sep 2024 | −$26.0M | — |
| 4 more quarters | Free account |
Against its own ten years
Low −$77.6M
High −$5.8M
Ten-year median
−$22.1M
Current reading's percentile
17
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR | −$77.6M |
| PTCT PTC Therapeutics, Inc. compare | −$106.0M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item